BiomX Inc. (PHGE-UN)
USD 0.9
(-5.26%)
USD 0.9
(-5.26%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -26.16 Million USD | 7.59% |
| 2022 | -28.31 Million USD | 21.83% |
| 2021 | -36.22 Million USD | -21.1% |
| 2020 | -29.91 Million USD | -58.12% |
| 2019 | -18.91 Million USD | -46.15% |
| 2018 | -12.94 Million USD | -101.23% |
| 2017 | -6.43 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -17.32 Million USD | -215.55% |
| 2024 Q2 | 4.47 Million USD | 125.8% |
| 2023 Q4 | -5.49 Million USD | -1337.43% |
| 2023 Q1 | -6.36 Million USD | -8.07% |
| 2023 FY | -26.16 Million USD | 7.59% |
| 2023 Q3 | -382 Thousand USD | 94.04% |
| 2023 Q2 | -6.41 Million USD | -0.79% |
| 2022 Q3 | -6.78 Million USD | 9.38% |
| 2022 FY | -28.31 Million USD | 21.83% |
| 2022 Q4 | -5.88 Million USD | 13.19% |
| 2022 Q2 | -7.48 Million USD | 8.41% |
| 2022 Q1 | -8.16 Million USD | 21.88% |
| 2021 Q2 | -7.33 Million USD | 12.69% |
| 2021 Q3 | -10.01 Million USD | -36.46% |
| 2021 Q4 | -10.45 Million USD | -4.46% |
| 2021 FY | -36.22 Million USD | -21.1% |
| 2021 Q1 | -8.4 Million USD | 8.11% |
| 2020 Q4 | -9.14 Million USD | -3.5% |
| 2020 Q3 | -8.83 Million USD | -42.36% |
| 2020 FY | -29.91 Million USD | -58.12% |
| 2020 Q1 | -5.9 Million USD | 73.43% |
| 2020 Q2 | -6.2 Million USD | -5.17% |
| 2019 Q1 | 280.6 Thousand USD | 2583.19% |
| 2019 Q4 | -22.2 Million USD | -7500.48% |
| 2019 Q3 | -292.17 Thousand USD | -612.68% |
| 2019 FY | -18.91 Million USD | -46.15% |
| 2019 Q2 | 56.99 Thousand USD | -79.69% |
| 2018 Q1 | -1000.00 USD | 0.0% |
| 2018 Q3 | -650.00 USD | 0.0% |
| 2018 Q4 | 10.45 Thousand USD | 1708.92% |
| 2018 FY | -12.94 Million USD | -101.23% |
| 2017 FY | -6.43 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -28.96 Million USD | 9.644% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -203.163% |
| Armata Pharmaceuticals, Inc. | -69.04 Million USD | 62.099% |
| Actinium Pharmaceuticals, Inc. | -48.81 Million USD | 46.395% |
| Azitra, Inc. | -11.28 Million USD | -131.917% |
| Can-Fite BioPharma Ltd. | -7.63 Million USD | -242.795% |
| Chromocell Therapeutics Corporation | -7.38 Million USD | -254.555% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | 10.429% |
| CEL-SCI Corporation | -32.36 Million USD | 19.146% |
| iBio, Inc. | -24.9 Million USD | -5.067% |
| Lineage Cell Therapeutics, Inc. | -21.48 Million USD | -21.796% |
| MAIA Biotechnology, Inc. | -19.77 Million USD | -32.348% |
| Matinas BioPharma Holdings, Inc. | -22.94 Million USD | -14.066% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -72.424% |
| NovaBay Pharmaceuticals, Inc. | -9.64 Million USD | -171.463% |
| NanoViricides, Inc. | -8.29 Million USD | -215.512% |
| Oragenics, Inc. | -20.65 Million USD | -26.691% |
| BiomX Inc. | -26.16 Million USD | -0.0% |
| Protalix BioTherapeutics, Inc. | 8.31 Million USD | 414.834% |
| Palatin Technologies, Inc. | -29.73 Million USD | 11.996% |
| Scorpius Holdings, Inc. | -45.21 Million USD | 42.126% |